急性冠状动脉综合征患者抗血小板药物抵抗的影响因素分析

doi:10.3969/j.issn.1006-7795.2021.05.016

摘要/Abstract

摘要： 目的探索分析急性冠状动脉综合征患者抗血小板药物抵抗的临床影响因素,以帮助临床医师快速识别出可能存在抗血小板药物氯吡格雷抵抗的患者。方法本研究纳入2013年全年在中国医学科学院阜外医院行冠状动脉介入术的急性冠状动脉综合征患者。依据血栓弹力图二磷酸腺苷诱导的血小板纤维蛋白凝块强度(adenosine diphosphate-induced platelet-fibrin clot strength,MA_ADP),将入选患者分为药物抵抗组 (MA_ADP>47 mm) 与非药物抵抗组(MA_ADP≤47 mm)。利用临床基线数据,采用单因素和多因素Logistic 回归分析筛选出与抗血小板药物氯吡格雷抵抗独立相关的影响因素。结果共2 511例患者被纳入本研究,其中有781例(31.10%)患者存在氯吡格雷治疗下的药物抵抗。通过单因素分析及进一步的多因素Logistic 回归分析,共筛选出肾功能异常(OR=3.08,95%CI:1.28~7.36)、女性(OR=2.86,95%CI:2.26~3.61)、合并糖尿病(OR=1.61,95%CI:1.33~1.95)、血小板增多(OR=1.55,95%CI:1.07~2.25)及质子泵抑制剂的使用(OR=1.25,95%CI:1.02~1.54)等5个与抗血小板药物抵抗有关的临床因素。结论肾功能异常、女性、合并糖尿病、血小板增多、使用质子泵抑制剂是患者发生抗血小板药物氯吡格雷抵抗的独立影响因素,在临床诊疗过程中需予以重点关注,从而指导个体化抗血小板治疗。

关键词: 抗血小板药物抵抗, 急性冠状动脉综合征, 影响因素, 血栓弹力图

Abstract: Objective To analyze the influencing factors of antiplatelet drug clopidogrel resistance in patients with acute coronary syndrome, so as to help clinicians quickly identify patients who may be resistant to antiplatelet therapy. Methods This study included patients with acute coronary syndrome who received coronary intervention and on dual antiplatelet at Fuwai Hospital throughout 2013. According to the results of thromboelastography (the result recorded as ADP-induced platelet-fibrin clot strength, MAADP,) the selected patients were divided into resistance group (MA_ADP>47 mm) and non-resistance group (MA_ADP≤47 mm). Via clinical data, univariate and multivariate logistic regression analysis were used to screen out influencing factors independently related to clopidogrel treatment resistance. Results A total of 2 511 patients were enrolled in the study, among them 781(31.10%) patients had clopidogrel treatment resistance. After univariate and further multivariate logistic regression analysis, five clinical factors were screened to be independently associated with resistance to antiplatelet therapy, namely reduced renal function (OR=3.08, 95%CI:1.28-7.36); female (OR=2.86, 95%CI:2.26-3.61); diabetes mellitus (OR=1.61, 95%CI:1.33-1.95); elevated platelet count (OR=1.55, 95%CI:1.07-2.25) and proton pump inhibitor use (OR=1.25, 95%CI:1.02-1.54). Conclusion Reduced renal function, female, diabetes, elevated platelet count and the use of proton pump inhibitors are the independent influencing factors of antiplatelet drug clopidogrel resistance in patients with acute coronary syndrome, which need to be paid attention in the clinical treatment, thereby guiding individualized antiplatelet therapy.

Key words: antiplatelet drug resistance, acute coronary syndrome, influencing factors, thromboelastography

中图分类号:

R541.4

姚懿, 唐晓芳, 宋莹, 姜琳, 乔树宾, 袁晋青. 急性冠状动脉综合征患者抗血小板药物抵抗的影响因素分析[J]. 首都医科大学学报, 2021, 42(5): 799-803.

Yao Yi, Tang Xiaofang, Song Ying, Jiang Lin, Qiao Shubin, Yuan Jinqing. Analysis on influencing factors of antiplatelet drug resistance in patients with acute coronary syndrome[J]. Journal of Capital Medical University, 2021, 42(5): 799-803.

参考文献

[1] Montalescot G, Sabatine M S. Oral dual antiplatelet therapy: what have we learnt from recent trials [J]. Eur Heart J,2016,37(4):344-352.
[2] Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients[J]. Eur Heart J, 2017, 38(14): 1034-1043.
[3] Dobesh P P, Finks S W, Trujillo T C. Dual antiplatelet therapy for long-term secondary prevention of atherosclerotic cardiovascular events[J]. Clin Ther,2020,42(10):2084-2097.
[4] Reny J L, Fontana P, Hochholzer W, et al. Vascular risk levels affect thepredictive value of platelet reactivity for the occurrence of MACE in patientson clopidogrel. Systematic review and meta-analysis of individual patientdata[J]. Thromb Haemost 2016,115:844-855.
[5] Notarangelo X F M,Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial[J]. J Am Coll Cardiol,2018,71(17): 1869-1877.
[6] Sibbing D, Aradi D, Alexopoulos D, et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y 12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention[J]. JACC Cardiovasc Interv, 2019,12(16):1521-1537.
[7] Tang F X, Han Y L, Zhang J H, et al. CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention[J]. Thromb Res, 2016,147:108-114.
[8] Tang N, Yin S Y, Sun Z Y, et al. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients[J] .Scand J Clin Lab Invest, 2015, 75(3):223-229.
[9] Li S, Liu H B, Liu J F, et al. Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation[J]. Platelets,2016,27(7):650-657.
[10]Cavallari L H, Lee C R, Beitelshees A L, et al. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention[J].JACC Cardiovasc Interv,2018,11(2): 181-191.
[11]Chen S X, Zhang Y, Wang L L, et al.Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI) [J]. Med Sci Monit, 2017,23:3824-3830.
[12]Sardella G, Calcagno S, Mancone M, et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel The RESET GENE Trial[J]. Circ Cardiovasc Interv, 2012, 5(5): 698-704.
[13]Htun P, Fateh-Moghadam S, Bischofs C, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention[J]. J Am Soc Nephrol, 2011, 22:627-633.
[14]Jain N, Li X, Adams-Huet B, et al. Differences in whole blood platelet aggregation at baseline and in response to aspirin and aspirin plus clopidogrel in patients with versus without chronic kidney disease[J]. Am J Cardiol,2016, 117:656-663.
[15]Capodanno D, Angiolillo D J. Impact of race and gender on antithrombotic therapy[J]. Thromb Haemost,2010,104:471-484.
[16]Jastrzebska M, Marcinowska Z, Oledzki S, et al. Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease[J]. J Physiol Pharmacol, 2018, 69(4):595-605.
[17]Marcucci R, Cioni G, Giusti B, et al. Gender and anti-thrombotic therapy: from biology to clinical implications[J]. J Cardiovasc Transl Res, 2014, 7:72-81.
[18]Geisler T, Mueller K, Aichele S, et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions[J]. Clin Res Cardiol, 2010,99:743-752.
[19]Kukula K, Klopotowski M, Was J, et al. Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin[J]. Postepy Kardiol Interwencyjnej, 2017, 13(3):210-217.
[20]谭知零.冠心病PCI患者服用双联抗血小板药物后氯吡格雷抵抗的发生情况及危险因素分析[J].解放军医药杂志,2018,30(6):75-78.
[21]Jakl M, Sevcik R, Ceral J, et al. Mean platelet volume and platelet count: overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome[J]. Anadolu Kardiyol Derg, 2014,14:85-86.
[22]Harvey A, Modak A, Dery U, et al. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity[J]. J Breath Res, 2016, 10:017104.
[23]Weisz G, Smilowitz N R, Kirtane A J, et al. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients:The ADAPT-DES Study[J]. Circ Cardiovasc Interv, 2015,8(10):e001952.